Atara biotherapeutics announces second quarter 2022 financial results and corporate strategy update

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2022, an update to its corporate strategy, recent business highlights, and key upcoming catalysts. “we are excited about the transformative potential of ata188 in ms and are pleased
ATRA Ratings Summary
ATRA Quant Ranking